ArticleDrug delivery and translational research2022
Gellan gum-based in situ gelling ophthalmic nanosuspension of Posaconazole.
Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 53 citations in OpenAlex.
- Gellan Gum Fluid Gel System for Controlled-Delivery of Cytokine-Licensed MSC-EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency.Advanced healthcare materials · 2026Article
- Smart In Situ-Forming Ocular Therapeutics for Dry Eye Disease: Bridging Biomaterials, Nanotechnology, and Clinical Translation.AAPS PharmSciTech · 2026Review
- Design and PreliminaryCurrent pharmaceutical biotechnology · 2026Article
- Overcoming corneal barriers: Posaconazole loaded cationic surfactant vesicles for enhanced ocular permeability and anti-fungal efficacy.Asian journal of pharmaceutical sciences · 2025Article
- Nanosuspension Innovations: Expanding Horizons in Drug Delivery Techniques.Pharmaceutics · 2025Review
- Development of ion-triggeredDrug delivery · 2024Article
- Preparation and in vivo and ex vivo studies of sirolimus nano-in-situ gel ophthalmic formulation.Journal of nanobiotechnology · 2024Article
- Development of a Resveratrol Nanoformulation for the Treatment of Diabetic Retinopathy.Materials (Basel, Switzerland) · 2024Article
- Preparation of Tamsulosin Hydrochloride-Loaded Mucoadhesive In Situ Gelling Polymeric Formulation for Nasal Delivery in Geriatrics.AAPS PharmSciTech · 2023Article
- Microbial Exopolysaccharide Composites in Biomedicine and Healthcare: Trends and Advances.Polymers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The formulation and delivery of highly hydrophobic drugs in an optimized dosage form is challenging to formulation scientists. Posaconazole has shown promising action in case studies against fungal keratitis. Biological macromolecules like gellan gum would aid in enhancing the availability of such drugs by increasing the contact time of the formulation. Herein, we propose a transmucosal ocular delivery system of Posaconazole by developing a gellan gum-based in situ gelling nanosuspension. The HPLC method for Posaconazole was developed and validated as per ICH guidelines. The nanosuspension was prepared by microfluidization and optimized by Quality by Design. The gellan gum concentration selected was 0.4% w/v based on the viscosity and mucoadhesion measurements. A greater zone of inhibition of ~ 15 mm was observed for the prepared nanosuspension as compared to ~ 11 mm for the marketed itraconazole nanosuspension. A potential irritancy score of 0.85, considered to be non-irritant, was observed for the developed nanosuspension. Higher drug release of ~ 35% was noted for the nanosuspension compared to about ~ 10% for the coarse suspension. Ex vivo corneal retention studies on excised goat cornea demonstrated ~ 70% drug retention in the tissue. Graphical abstract depicting the central hypothesis of the work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.